Cargando…
SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
SLAMF6 is a homotypic receptor of the Ig-superfamily whose exact role in immune modulation has remained elusive. Its constitutive expression on resting and activated T cells precludes it from being a bona fide exhaustion marker. By breeding Pmel-1 mice with SLAMF6 -/- mice, we generated donors for T...
Autores principales: | Hajaj, Emma, Eisenberg, Galit, Klein, Shiri, Frankenburg, Shoshana, Merims, Sharon, Ben David, Inna, Eisenhaure, Thomas, Henrickson, Sarah E, Villani, Alexandra Chloé, Hacohen, Nir, Abudi, Nathalie, Abramovich, Rinat, Cohen, Jonathan E, Peretz, Tamar, Veillette, Andre, Lotem, Michal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075692/ https://www.ncbi.nlm.nih.gov/pubmed/32122464 http://dx.doi.org/10.7554/eLife.52539 |
Ejemplares similares
-
Human T Cell Crosstalk Is Induced by Tumor Membrane Transfer
por: Uzana, Ronny, et al.
Publicado: (2015) -
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study
por: Hadash-Bengad, Reut, et al.
Publicado: (2020) -
The future of affordable cancer immunotherapy
por: Schaft, Niels, et al.
Publicado: (2023) -
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
por: Lotem, M, et al.
Publicado: (2004) -
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade
por: Lotem, Michal, et al.
Publicado: (2016)